237
0 Kommentare
Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman
237 
0 Kommentare- Inge Beernaert appointed President of the Compensation and Nomination Committee
- Jacques Galloy appointed President of the Audit Committee
Liege, Belgium, 29 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the appointment of leading life sciences executive Dr.Christian Homsy as Chairman of the Board of Directors.
The Board of Directors also appointed Inge Beernaert as President of the Compensation and Nomination Committee and Gaudeto, represented by Jacques Galloy as President of the Audit Committee”
Dr. David Horn Solomon, Chief Executive Officer of Mithra, commented: “I am delighted that our board of directors has elected Dr. Christian Homsy as Chairman. Christian brings valuable competencies and a long record of success in our industry. His experience provides stability and perspective, invaluable assets to Mithra during this ongoing transition as we pursue our ambition to become a global leader in women’s health.”
Christian Homsy*, who recently joined the Board as an Independent Director of Mithra, has more than 30 years’ experience in the life sciences industry, most recently as founder and interim Chief Executive Officer and Board Member of biotechnology company Capstan Therapeutics. He was also founder, Chief Executive Officer and Board Member of the Euronext and U.S. Nasdaq listed Belgian biotechnology company Celyad SA and spent the first part of his career in senior roles at Guidant Corporation, now part of Boston Scientific and Abbott. Christian gained his Medical Doctorate at the University of Louvain, Belgium and his MBA at IMD Business School, Lausanne, Switzerland.
Lesen Sie auch
Dr. Christian Homsy*, Chairman of Mithra, commented: “I look forward to work closely with our new CEO David Horn Solomon, the rest of the Mithra leadership and the newly elected Board of Directors. The new Board of Directors is fully aligned with the company’s new strategy, shared by David in his letter to shareholders and discussed last week at our annual general meeting. The coming period promises to be transformational for Mithra as we increase our focus on Mithra’s core strength, development and commercialization of best-in-class innovative novel therapeutics for women’s health.
Aktuelle Themen
Weitere Artikel des Autors
URL kopieren
Per E-Mail teilen
Artikel drucken
Auch bei Lesern beliebt
